Cybin (HELP) EBT (2020 - 2022)
Cybin (HELP) posted quarterly EBT of $4.6 million for Q2 2022, up 186.82% on a QoQ basis from -$5.2 million in Q1 2021.
Cybin (HELP) EBT (2020 - 2022) Analysis & Trends
Cybin (HELP) has reported EBT for 3 consecutive years, with $4.6 million the latest figure, recorded in Q2 2022.
- Quarterly EBT changed N/A year-over-year to $4.6 million in Q2 2022, while the trailing twelve-month figure through May 2022 was -$162.8 million (changed N/A YoY) and the FY2026 annual result came in at -$147.8 million, down 53.91% from the prior year.
- EBT improved to $4.6 million in Q2 2022 per HELP's latest filing, from -$5.2 million in the prior quarter.
- Over the last five years, EBT for HELP reached as high as $144.2 million in Q2 2020 and fell as low as -$162.1 million in Q4 2020.
- A 3-year average of -$3.7 million and a median of -$1921.8 in 2020 frame the typical range for EBT.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2021 | -5.24 Mn |
| Dec 31, 2020 | -162.13 Mn |
| Sep 30, 2020 | -1,921.84 |
| Jun 30, 2020 | 144.24 Mn |